Activity Goal The goal of this educational initiative is to disseminate to physicians recent, clinically focused evidence on optimizing the long-term management of Crohn’s disease (CD), including discussion of aggressive therapy early in the course of disease. Statement of Need Crohn’s disease is a chronic, progressive, often debilitating condition that affects more than 500,000 individuals in the United States. This disorder results from a complex interplay of genetic, environmental, and immunoregulatory factors, although a precise etiology has not been clarified. Despite an array of effective treatment options, the long-term management of CD often is marked by a relapsing-remitting course and significant complications such as strictures, fistulas, extraintestinal manifestations, and colorectal cancer. Indeed, surgical intervention is required in most patients receiving standard sequential therapies for CD. This situation has prompted an earnest reappraisal of optimal approaches to therapy with the goal of improving the delivery of care to patients with this challenging condition. Learners Gap This activity will arm clinicians with current, accurate, and relevant information exemplified by true-to-life case examples from leading thought leaders, for use in daily practice with the ultimate goal of improving the management and quality of life of patients with CD. Intended Audience This activity is intended for physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. There are no prerequisites for this educational activity. Conflict of Interest Statement The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationships with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience discussion of any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Learning Objectives At the completion of this activity, participants should be better prepared to: Delineate the clinical characteristics and symptoms of CD, including extraintestinal manifestations. Understand the appropriate use of biomarkers in determining disease prognosis and identifying candidates for various therapies. Compare evidence-based approaches for the management of CD, particularly with regard to monotherapy versus combination therapy; bottom-up versus top-down approaches; and the selection, timing, and duration of therapy. Discuss the relative effi cacy and clinical profiles of currently available biologic and nonbiologic pharmacologic therapies, and appropriate parameters for monitoring effectiveness and adverse events. Understand and manage potential adverse events associated with the use of biologic therapy for the treatment of CD, such as the development of serious infections. Faculty Lawrence J. Brandt, MD Course Director Professor Department of Surgery Chief Division of Gastroenterology Department of Medicine Maria Teresa Abreu, MD Chief Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida Gary R. Lichtenstein, MD Program Chair Professor of Medicine University of Pennsylvania School of Medicine Director, Center for Inflammatory Bowel Diseases Philadelphia, PA David T. Rubin, MD Associate Professor of Medicine Program Director The Fellowship in Gastroenterology, Hepatology, and Nutrition Co-Director The Inflammatory Bowel Disease Center Special Needs Albert Einstein College of Medicine fully intends to comply with the legal requirements of the Americans with Disabilities Act. If any participant of the Optimizing the Management of Optimizing the Management of Crohn’s Disease in the Era of Biologics symposium given by Albert Einstein College of Medicine is in need of accommodations, please do not hesitate to submit written requests to Barbara Jean Wynne at BWynne@appliedcme.com, at least 2 weeks prior to the activity.	Jointly sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, and Applied Clinical Education. This activity is supported by an independent educational grant from UCB Pharma. Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine, Montefiore Medical Center, and Applied Clinical Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Albert Einstein College of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.